Congress of the European Society of Clinical Microbiology and Infectious Diseases

Vienna, Austria 11 April 2025 - 15 April 2025

Ibrexafungerp expands salvage antifungal treatment options as a pill

25 Jun 2025 by

For patients with fungal diseases that preclude receiving standard treatment or IV antifungals primarily due to refractoriness or resistance, ibrexafungerp can serve as an effective salvage treatment given orally, offering a positive risk-benefit ratio up to the final data cut-off in the FURI trial

Ibrexafungerp expands salvage antifungal treatment options as a pill

25 Jun 2025

RSV-ARI nearly triples mortality risk in new study

18 Jun 2025 by

Acute respiratory infection caused by respiratory syncytial virus (RSV-ARI) nearly triples the risk of death, particularly among individuals with chronic underlying respiratory conditions, as shown in a nationwide cohort study in Denmark.

RSV-ARI nearly triples mortality risk in new study

18 Jun 2025

FMT bodes well for AMR

27 May 2025 by

The PROFIT trial turns waste into gains by showing how faecal microbiota transplantation (FMT) can combat antimicrobial resistance (AMR) in patients with liver cirrhosis.

FMT bodes well for AMR

27 May 2025

TrUST study heralds new era for TB diagnosis

21 May 2025 by

A suite of deep learning (DL) models to automate tuberculosis (TB) risk assessment from lung ultrasound (LUS) images fulfils the WHO criteria for a sputum-free TB triage test and outwits human experts in the TrUST study.

TrUST study heralds new era for TB diagnosis

21 May 2025

Dual therapy as good as three-drug HIV regimen in patients coinfected with TB

19 May 2025 by

In the treatment of HIV in individuals who are receiving rifampin-based therapy for tuberculosis, a two-drug antiretroviral (ART) regimen comprising double-dose dolutegravir plus lamivudine compares favourably with a three-drug regimen of efavirenz, tenofovir, and lamivudine in terms of suppressing viral load, as shown in a study.

Dual therapy as good as three-drug HIV regimen in patients coinfected with TB

19 May 2025

Tapered vancomycin dosing reduces CDI recurrence

18 May 2025 by

Tapering the dose of vancomycin over 2 weeks following initial 14-day therapy appears to work better than the 14-day fixed dosing at reducing the recurrence of Clostridioides difficile infection (CDI), as shown in the TAPER-V trial.

Tapered vancomycin dosing reduces CDI recurrence

18 May 2025

Temocillin a good alternative to carbapenems for bacteraemia

16 May 2025 by

The use of temocillin demonstrates comparable efficacy and safety to carbapenems for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (3GCR-E), primarily from urinary sources, reports a study.

Temocillin a good alternative to carbapenems for bacteraemia

16 May 2025

5-day antibiotic use viable in CAP patients with clinical stability

16 May 2025 by

Antibiotic treatment may be done for 5 days, as opposed to at least 7 days, in hospitalized patients with community-acquired pneumonia (CAP) who had achieved clinical stability by day 3 to 5, suggests a study presented at ESCMID Global 2025.

5-day antibiotic use viable in CAP patients with clinical stability

16 May 2025

Single-dose RSVPreF3 OA vaccine effective over 3 RSV seasons in seniors

07 May 2025 by

A single dose of adjuvanted respiratory syncytial virus (RSV) prefusion F protein–based vaccine (RSVPreF3 OA) is efficacious against RSV-related lower respiratory tract disease (RSV-LRTD) over three RSV seasons in older adults aged ≥60 years, according to results of the phase III AReSVi-006 trial presented at ESCMID Global 2025.

Single-dose RSVPreF3 OA vaccine effective over 3 RSV seasons in seniors

07 May 2025

BNT162b2 JN.1-adapted vaccine effective against COVID-19 hospitalization

06 May 2025 by

BNT162b2 JN.1-adapted vaccine provides protection against COVID-19–related hospitalization in Europe, a case-control study using the id.DRIVE platform has shown.

BNT162b2 JN.1-adapted vaccine effective against COVID-19 hospitalization

06 May 2025